Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample

Cognitive impairment occurs at higher rates in individuals at clinical high risk (CHR) for psychosis relative to healthy peers, and it contributes unique variance to multivariate prediction models of transition to psychosis. Such impairment is considered a core biomarker of schizophrenia. Thus, cognition is a key domain measured in the Accelerating Medicines Partnership® program for Schizophrenia (AMP SCZ initiative). The aim of this paper is to describe the rationale, processes, considerations, and final harmonization of the cognitive battery used in AMP SCZ across the two data collection networks. This battery comprises tests of general intellect and specific cognitive domains. We estimate premorbid intelligence at baseline and measure current intelligence at baseline and 2 years. Eight tests from the Penn Computerized Neurocognitive Battery (PennCNB), which measure verbal learning and memory, sensorimotor ability, attention, emotion recognition, working memory, processing speed, verbal memory, visual memory, and motor speed are administered repeatedly at baseline, and four follow-up timepoints over 2 years.

Authors

Institutions

Publication Details

Journal
Schizophrenia
Published
2025-03-24
DOI
https://doi.org/10.1038/s41537-025-00578-1
Citations
8
Primary Topic
Schizophrenia research and treatment
Type
article
Field-Weighted Citation Impact
11.77

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample

Michael J. Coleman, Matcheri S. Keshavan, Sylvain Bouix, Celso Arango et al.
8 citations
Schizophrenia
Schizophrenia research and treatment
11.77
article

Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample

Michael J. Coleman, Matcheri S. Keshavan, Sylvain Bouix, Celso Arango, Barbara A. Cornblatt, Alan Anticevic, John M. Kane, Diana O. Perkins, Nora Penzel, Jai L. Shah, Albert R. Powers, Godfrey D. Pearlson, Carrie E. Bearden, Fred W. Sabb, Kerstin Langbein, Nicholas J. K. Breitborde, Jason Eric Schiffman, Danielle McLaughlin, Gregory P. Strauss, Jijun Wang, Philippe Conus, Daniel H. Mathalon, Luis Alameda, Walid Yassin, Swapna Verma, Lana Kambeitz‐Ilankovic, Jun Soo Kwon, Stephen James Wood, Dominic Dwyer, Sinéad Kelly, René S. Kahn, Tashrif Billah, Matthew R. Broome, Kristina Ballestad Gundersen, Priya Matneja, Covadonga M. Díaz‐Caneja, Merete Nordentoft, Steven M. Silverstein, Jack Rogers, Carla Gerber, Ofer Pasternak, Ricardo E. Carrión, Kosha Ruparel, Jessica Spark, Christy Lai Ming Hui, Barnaby Nelson, Pablo A. Gaspar, Judy L. Thompson, G Santorelli, Jean Addington, Cheryl M. Corcoran, Jesús Pérez, Susan Ray, Rachel Upthegrove, William S. Stone, Patrick D. McGorry, Ruben C. Gur, Jenna Reinen, Kristyn Chin, Kathryn E. Lewandowski, Paolo Fusar‐Poli, Gil D. Hoftman, Alan J. Thompson, Beau‐Luke Colton, Daniel Mamah, Zailyn Tamayo, Monica E. Calkins, Kate Buccilli, Kelly Allott, Sophie Tod, Rolando I Castillo-Passi, Scott W. Woods, Michael Sand, Stefan Smesny, Kristin S. Cadenhead, Patricia Marcy, Johanna Seitz‐Holland, Eirini Zoupou, Martha E. Shenton, Cassandra M. J. Wannan, Daniel H. Wolf, Grace R. Jacobs, Setari Parsa, Joseph Kambeitz, Vijay Anand Mittal, Sebastián A. Corral, Louise Birkedal Glenthøj, Leslie E. Horton, Nikolaos Koutsouleris, Owen Borders, Kang Ik K. Cho, Sung‐Wan Kim, Eric Yu Hai Chen, Jimmy Choi, Alana Wickham, Ángela Núñez, Lauren M. Ellman
article en
8 citations

Abstract

Cognitive impairment occurs at higher rates in individuals at clinical high risk (CHR) for psychosis relative to healthy peers, and it contributes unique variance to multivariate prediction models of transition to psychosis. Such impairment is considered a core biomarker of schizophrenia. Thus, cognition is a key domain measured in the Accelerating Medicines Partnership® program for Schizophrenia (AMP SCZ initiative). The aim of this paper is to describe the rationale, processes, considerations, and final harmonization of the cognitive battery used in AMP SCZ across the two data collection networks. This battery comprises tests of general intellect and specific cognitive domains. We estimate premorbid intelligence at baseline and measure current intelligence at baseline and 2 years. Eight tests from the Penn Computerized Neurocognitive Battery (PennCNB), which measure verbal learning and memory, sensorimotor ability, attention, emotion recognition, working memory, processing speed, verbal memory, visual memory, and motor speed are administered repeatedly at baseline, and four follow-up timepoints over 2 years.

SchizophreniaVol. 11(1)
Chonnam National University (KR), Northwestern University (US), University of North Carolina at Chapel Hill (US), University of Copenhagen (DK), Brigham and Women's Hospital (US), Hartford Hospital (US), Northwell Health (US), Beth Israel Deaconess Medical Center (US), Oregon Research Institute (US), Feinstein Institute for Medical Research (US), Universidad del Desarrollo (CL), Harvard University (US), Seoul National University (KR), University of California, Los Angeles (US), University of Georgia (US), The University of Melbourne (AU), University of Calgary (CA), University of Pittsburgh (US), Douglas College (CA), University of California, San Francisco (US), University of Cologne (DE), University of Oregon (US), King's College London (GB), Universidad de Salamanca (ES), University of California, Irvine (US), Washington University in St. Louis (US), University of Pavia (IT), Massachusetts Mental Health Center (US), McLean Hospital (US), Instituto de Salud Carlos III (ES), Copenhagen University Hospital (DK), Shanghai Mental Health Center (CN), Seoul National University Hospital (KR), University of Rochester Medical Center (US), Hospital General Universitario Gregorio Marañón (ES), Yale University (US), University of California San Diego (US), University of Oxford (GB), Massachusetts General Hospital (US), Centro de Investigación Biomédica en Red de Salud Mental (ES), Orygen Youth Health (AU), Donald & Barbara Zucker School of Medicine at Hofstra/Northwell (US), Orygen (AU), IBM Research - Thomas J. Watson Research Center (US), Duke-NUS Medical School (SG), Instituto de Investigación Biomédica de Salamanca (ES), Jena University Hospital (DE), Behavioral Health Network (US), Institute of Mental Health (SG), San Francisco VA Health Care System (US), Cambridgeshire and Peterborough NHS Foundation Trust (GB), University Hospital Cologne (DE), Birmingham Women’s and Children’s NHS Foundation Trust (GB), Connecticut Mental Health Center (US), Hotchkiss Brain Institute (CA), McGill University (CA), The Ohio State University (US), University of Chile (CL), University of La Serena (CL), University of Pennsylvania (US), University of Birmingham (GB), Ludwig-Maximilians-Universität München (DE), Temple University (US), University of Hong Kong (HK), École de Technologie Supérieure (CA), University of Lausanne (CH), Icahn School of Medicine at Mount Sinai (US)
U.S. Department of Veterans Affairs, Bristol-Myers Squibb, Pfizer, Wellcome, Brigham and Women's Hospital, Massachusetts General Hospital, Yale University, Biogen, Teva Pharmaceutical Industries, McLean Hospital, University of Pennsylvania, Ohio State University, Northwestern University, University of Pittsburgh, McGill University, Hotchkiss Brain Institute, University of Calgary, Sunovion, Temple University, University of Oregon, Indivior, Birmingham Women's and Children's NHS Foundation Trust, Northwell Health, University of Warwick, King's College London, University of Oxford, University of Melbourne, Chonnam National University, Seoul National University, Gentofte Hospital, Gedeon Richter, Seoul National University Hospital, Università degli Studi di Pavia, Ministerio de Ciencia e Innovación, Universidad de Chile, Université de Lausanne, Centre Hospitalier Universitaire Vaudois, Centro de Investigación Biomédica en Red de Salud Mental, Universitätsklinikum Jena, Universität zu Köln, Servier, H. Lundbeck A/S, Universidad de Salamanca, Clínica Alemana de Santiago, Instituto de Investigación Sanitaria Gregorio Marañón, HLS Therapeutics, National Institutes of Health, Allergan, University of North Carolina at Chapel Hill, University of California, San Diego, Perelman School of Medicine, University of Pennsylvania, University of California, San Francisco, University of California, Irvine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, College of Medicine, Seoul National University, Warwick Medical School, Instituto de Salud Carlos III, National Institute of Mental Health, Cilag
Partnerships for the goals
Openalex Percentile: Top 1%
Schizophrenia research and treatment
11.77
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.